The potential use of therapeutics and prophylactic mRNA vaccines in human papillomavirus (HPV) DOI Creative Commons

Fatemeh Movahed,

Satinik Darzi,

Parya Mahdavi

et al.

Virology Journal, Journal Year: 2024, Volume and Issue: 21(1)

Published: May 31, 2024

Abstract Cervical cancer (CC) and other malignant malignancies are acknowledged to be primarily caused by persistent human papillomavirus (HPV) infection. Historically, vaccinations against viruses that produce neutralizing antibodies unique the virus have been an affordable way manage viral diseases. CC risk is decreased, but not eliminated, HPV vaccinations. Since made available globally, almost 90% of infections successfully avoided. On lesions diseases already present, however, no discernible treatment benefit has shown. As a result, therapeutic vaccines elicit immune responses mediated cells necessary for established cancers. mRNA possess remarkable potential in combating malignancy as result their superior industrial production, safety, efficacy. Furthermore, considering expeditiousness vaccine exhibits promise approach targeting HPV. Given HPV-encoded early proteins, including oncoproteins E6 E7, consistently present HPV-related cancers pre-cancerous crucial functions progression persistence diseases, they serve ideal targets vaccines. The action mechanism vaccines, recent advancements clinical trials, applications highlighted this study, which also offers quick summary state Lastly, we highlight few difficulties with vaccination practice provide our thoughts on further quickly changing sector. It expected will soon produced prevention treatment. Graphical

Language: Английский

HPV post-infection microenvironment and cervical cancer DOI
Yi Yuan, Xushan Cai,

Fangrong Shen

et al.

Cancer Letters, Journal Year: 2020, Volume and Issue: 497, P. 243 - 254

Published: Oct. 27, 2020

Language: Английский

Citations

179
Virus-like particle vaccinology, from bench to bedside DOI Creative Commons
Mona O. Mohsen, Martin F. Bachmann

Cellular and Molecular Immunology, Journal Year: 2022, Volume and Issue: 19(9), P. 993 - 1011

Published: Aug. 12, 2022

Virus-like particles (VLPs) have become key tools in biology, medicine and even engineering. After their initial use to resolve viral structures at the atomic level, VLPs were rapidly harnessed develop antiviral vaccines followed by as display platforms generate any kind of vaccine. Most recently, been employed nanomachines deliver pharmaceutically active products specific sites into cells body. Here, we focus on for development with broad fields indications ranging from classical against viruses therapeutic chronic inflammation, pain, allergy cancer. In this review, take a walk through time, starting latest developments experimental preclinical VLP-based ending marketed vaccines, which earn billions dollars every year, paving way next wave prophylactic already visible horizon.

Language: Английский

Citations

155
Trends of cervical cancer at global, regional, and national level: data from the Global Burden of Disease study 2019 DOI Creative Commons
Xingxing Zhang,

Qingle Zeng,

Wenwen Cai

et al.

BMC Public Health, Journal Year: 2021, Volume and Issue: 21(1)

Published: May 12, 2021

Cervical cancer is an important global health problem. In this study we aimed to analyze trends in cervical at the global, regional, and national levels from 1990 2019, inform service decision-making.Data on was extracted Global Burden of Disease study, 2019. Trends burden were assessed based estimated annual percentage change (EAPC) age-standardized rate (ASR).Globally, decreasing observed incidence, death, disability adjusted life years (DALYs) with respective EAPCs - 0.38 (95% confidence interval [CI]: 0.41 0.34), 0.93 (95%CI: 0.98 0.88), 0.95 (95 CI%: 1.00 0.90). Meanwhile, detected most sociodemographic index (SDI) areas geographic regions, particularly death DALYs Central Latin America, 2.61 CI: 2.76 2.46) 2.48 2.63 2.32); hhowever, a pronounced increasing trend incidence occurred East Asia (EAPC = 1.33; 95% 1.12 1.55). At level, countries/territories, Maldives 5.06; 5.40 4.72), Whereas Lesotho, Zimbabwe, Bulgaria.Slowly worldwide remains substantial problem for women globally, requiring more effective prevention control strategies.

Language: Английский

Citations

140
Sexually transmitted infections and female reproductive health DOI Open Access
Olivia T. Van Gerwen, Christina A. Muzny, Jeanne Marrazzo

et al.

Nature Microbiology, Journal Year: 2022, Volume and Issue: 7(8), P. 1116 - 1126

Published: Aug. 2, 2022

Language: Английский

Citations

124
Prophylactic and Therapeutic HPV Vaccines: Current Scenario and Perspectives DOI Creative Commons

Yicheng Mo,

Jiabing Ma,

Hongtao Zhang

et al.

Frontiers in Cellular and Infection Microbiology, Journal Year: 2022, Volume and Issue: 12

Published: July 4, 2022

Persistent human papillomavirus (HPV) infection is recognized as the main cause of cervical cancer and other malignant cancers. Although early detection treatment can be achieved by effective HPV screening methods surgical procedures, disease load has not been adequately mitigated yet, especially in underdeveloped areas. Vaccine, being regarded a more solution, expected to prevent virus consequent diseases phases both prevention treatment. Currently, there are three licensed prophylactic vaccines for L1-VLPs, namely bivalent, quadrivalent nonavalent vaccine. About 90% infections have effectively prevented with implementation worldwide. However, no significant therapeutic effect observed on already existed lesions. Therapeutic vaccine designed oncoprotein E6/E7 activates cellular immunity rather than focuses neutralizing antibodies, which considered an ideal immune method eliminate infection. In this review, we elaborate classification, mechanism, clinical effects treatment, order make improvements current situation provoking new ideas.

Language: Английский

Citations

96
Integration of immunotherapy into treatment of cervical cancer: Recent data and ongoing trials DOI Creative Commons
Bradley J. Monk, Takayuki Enomoto, W. Martin Kast

et al.

Cancer Treatment Reviews, Journal Year: 2022, Volume and Issue: 106, P. 102385 - 102385

Published: April 1, 2022

Cervical cancer constitutes a significant health burden for women globally. While most patients with early-stage disease can be cured radical surgery or chemoradiotherapy, high-risk locally advanced recurrent/metastatic have poor prognosis standard treatments. Immunotherapies are rational treatment this HPV-driven that commonly expresses programmed cell death ligand-1. Before 2021, pembrolizumab was the only United States Food and Drug Administration-approved immunotherapy in cervical cancer, specifically second-line recurrent metastatic (r/m) setting. In late antibody-drug conjugate tisotumab vedotin approved r/m combined chemotherapy ± bevacizumab first-line based on results from KEYNOTE-826. Moreover, at least 2 dozen additional clinical trials setting, as well disease, landscape may eventually encounter potential paradigm shift. Pivotal of immunotherapies were recently regulatory consideration through 2024 reviewed. As has opportunity to establish new standards care cancers, biomarkers identify ideal patient populations these therapies also become important. However, issues access, affordability, compliance low- middle-income countries anticipated.

Language: Английский

Citations

92
Overview and countermeasures of cancer burden in China DOI Open Access

Yian Wang,

Qijia Yan,

Chunmei Fan

et al.

Science China Life Sciences, Journal Year: 2023, Volume and Issue: 66(11), P. 2515 - 2526

Published: April 13, 2023

Language: Английский

Citations

88
Immunologic tumor microenvironment modulators for turning cold tumors hot DOI Creative Commons
Gholamreza Khosravi, Samaneh Mostafavi,

Sanaz Bastan

et al.

Cancer Communications, Journal Year: 2024, Volume and Issue: 44(5), P. 521 - 553

Published: March 29, 2024

Abstract Tumors can be classified into distinct immunophenotypes based on the presence and arrangement of cytotoxic immune cells within tumor microenvironment (TME). Hot tumors, characterized by heightened activity responsiveness to checkpoint inhibitors (ICIs), stand in stark contrast cold which lack infiltration remain resistant therapy. To overcome evasion mechanisms employed cells, novel immunologic modulators have emerged, particularly ICIs targeting T‐lymphocyte‐associated protein 4 (CTLA‐4) programmed cell death 1/programmed death‐ligand 1(PD‐1/PD‐L1). These agents disrupt inhibitory signals reactivate system, transforming tumors hot ones promoting effective antitumor responses. However, challenges persist, including primary resistance immunotherapy, autoimmune side effects, response heterogeneity. Addressing these requires innovative strategies, deeper mechanistic insights, a combination interventions enhance effectiveness immunotherapies. In landscape cancer medicine, where represent formidable hurdle, understanding TME harnessing its potential reprogram is paramount. This review sheds light current advancements future directions quest for more safer treatment offering hope patients with immune‐resistant tumors.

Language: Английский

Citations

68
Updates on HPV Vaccination DOI Creative Commons
Ojone Illah,

Adeola Olaitan

Diagnostics, Journal Year: 2023, Volume and Issue: 13(2), P. 243 - 243

Published: Jan. 9, 2023

Cervical cancer still poses a significant global challenge. Developed countries have mitigated this challenge by the introduction of structured screening programmes and, more recently, HPV vaccine. Countries that successfully introduced national vaccination are on course for cervical elimination in few decades. In developing lack and programmes, remains major cause morbidity mortality. The vaccine is key to addressing disproportionate distribution incidence, with much be gained from increasing coverage uptake globally. This review covers history science vaccine, its efficacy, effectiveness safety, some considerations challenges posed achievement consequent cancer.

Language: Английский

Citations

67
Two centuries of vaccination: historical and conceptual approach and future perspectives DOI Creative Commons
David A. Montero, Roberto Vidal,

Juliana Velasco

et al.

Frontiers in Public Health, Journal Year: 2024, Volume and Issue: 11

Published: Jan. 9, 2024

Over the past two centuries, vaccines have been critical for prevention of infectious diseases and are considered milestones in medical public health history. The World Health Organization estimates that vaccination currently prevents approximately 3.5-5 million deaths annually, attributed to such as diphtheria, tetanus, pertussis, influenza, measles. Vaccination has instrumental eradicating important pathogens, including smallpox virus wild poliovirus types 2 3. This narrative review offers a detailed journey through history advancements vaccinology, tailored healthcare workers. It traces pivotal milestones, beginning with variolation practices early 17th century, development first vaccine, continuous evolution innovation vaccine up present day. We also briefly immunological principles underlying vaccination, well main types, special mention recently introduced mRNA technology. Additionally, we discuss broad benefits vaccines, their role reducing morbidity mortality, fostering socioeconomic communities. Finally, address issue hesitancy effective strategies promote acceptance. Research, collaboration, widespread acceptance use imperative continued success programs controlling ultimately diseases.

Language: Английский

Citations

40